Permanent vision loss can occur, particularly in patients with advanced baseline retinopathy, severe bleeding, retinal detachment, or delayed treatment
Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes management, not weight loss
Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial
Three new use cases for GLP-1s GLP-1 drugs were first licensed by the FDA in 2005 and have been prescribed for people with type 2 diabetes and obesity for almost 20 years
Clinical trial data for GLP-1 medicines, including Ozempic, Mounjaro, Wegovy/Wegovy HD, Zepbound, and Foundayo, were reviewed to compare reported weight-loss results, FDA-approved uses, and study limitations
Comparison table Side effects and safety profiles The side effect profiles of Qsymia and GLP-1 medications reflect their fundamentally different mechanisms